Parab, P., Juthani, R., Seetharaman, K. (2025). Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for urothelial cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.680